Chemotherapy News and Research

Latest Chemotherapy News and Research

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

Dutch investigators have reported that women who received CMF chemotherapy (a combination regimen including the drugs cyclophosphamide, methotrexate, and 5-fluorouracil) for breast cancer between 1976 and 1995 scored worse on cognitive tests than women who never had cancer.

28 Feb 2012

Aurora-A protein blocks proper functioning of tumor-suppressor p73

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

28 Feb 2012

Viewpoints: Santorum on repeal; Ariz. Republic endorses Romney; How Catholic church almost accepted birth control

I'll submit legislation to repeal ObamaCare, and on day one issue an executive order ending related regulatory obligations on the states. I'll work with Congress to replace ObamaCare with competitive insurance choices to improve quality and limit the costs of health care, while protecting those with uninsurable health conditions.

28 Feb 2012

Rare egg producing stem cells in women’s ovaries discovered

It was known till now that women were born with all the eggs they'll ever have. But now Harvard scientists have found that ovaries of young women harbor very rare stem cells capable of producing new eggs. The researchers feel that harnessing those stem cells might one day lead to better treatments for women left infertile because of disease or age.

27 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

First patients in Germany treated with Delcath Hepatic CHEMOSAT Delivery System

Delcath Systems, Inc., announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

27 Feb 2012

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

A Saint Louis University investigator noted for her pain research is working to reduce a painful chemotherapy side effect, thanks to a $126,500 grant from the Mayday Fund, an organization dedicated to alleviating the incidence, degree and consequence of human physical pain.

27 Feb 2012

MGH scientists isolate OSCs from ovaries of reproductive age women

For the first time, Massachusetts General Hospital (MGH) researchers have isolated egg-producing stem cells from the ovaries of reproductive age women and shown these cells can produce what appear to be normal egg cells or oocytes.

27 Feb 2012

New, less toxic radiotherapy technique specifically targets cancerous tissue

Researchers at the University of Granada and the university hospital Virgen de las Nieves in Granada have developed a new radiotherapy technique that is much less toxic than that traditionally used and only targets cancerous tissue.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

FDA, pharmaceutical companies announce solution to cancer drug shortage

The U.S. Food and Drug Administration and several pharmaceutical companies said Tuesday they have reached agreements to alleviate shortages for the drugs methotrexate and Doxil. Methotrexate is used to treat children with a form of leukemia and others with tumors of the breast and lungs. Doxil is used to treat ovarian cancer and multiple myeloma.

23 Feb 2012

Women over 40 have better prognosis after mammography screening

Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology.

23 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

New analysis highlights ongoing scale of tobacco problem among children

Every year around 157,000 children aged 11-15 start smoking - that's enough to fill 5,200 classrooms or make up nearly 14,000 junior football teams. These shocking figures, revealed in a new analysis by Cancer Research UK, highlight the ongoing scale of the tobacco problem, and underline the importance of sustained action to discourage young people from starting to smoke, including by introducing plain packaging for all tobacco products as soon as possible.

22 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

OGF-OGFr axis discovery provides new insights into ovarian cancer

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the presence and integrity of the opioid growth factor receptor (OGFr), which mediates the inhibitory action of opioid growth factor (OGF) on cell proliferation, is a key to understanding the progression and treatment of human ovarian cancer.

22 Feb 2012

Mitochondria may be promising new target for cancer treatment

Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB.

22 Feb 2012

Combination of gemcitabine and MRK003 kills pancreatic cancer cells

Cancer Research UK scientists have revealed how a combination of two very different drugs - currently being tested in clinical trials - amplifies the destruction of pancreatic cancer cells, according to research published in the Journal of Experimental Medicine, today.

22 Feb 2012